secwatch.observer — SEC 8-K summary
======================================

Issuer:     Paysign, Inc. (PAYS)
CIK:        0001496443
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001683168-26-002168
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Paysign FY2025 revenue $82.0M (+40.5%); guides FY2026 revenue $106.5-110.5M, net income nearly doubles
--------------------------------------------------------------------------------

- Full-year 2025 total revenues $82.0M (up 40.5% YoY); net income $7.55M ($0.13 diluted EPS) vs $3.82M ($0.07) in 2024.
- Adjusted EBITDA $19.94M (up 107.3% YoY); pharma revenue +167.8% to $33.89M on 55 new patient affordability programs.
- Added 115 net plasma centers (595 total); plasma revenue +4.0% to $45.62M.
- Gamma acquisition (BECS under FDA review) closed March 2025; exited with $21.07M cash, zero debt.
- FY2026 guidance: revenue $106.5-110.5M (30-35% growth), net income $13-16M ($0.21-0.26 EPS), adjusted EBITDA $30-33M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496443/000168316826002168/0001683168-26-002168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496443/000168316826002168/paysign_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-002168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer